BioCentury
ARTICLE | Company News

Biogen Idec grants UCB commercialization rights in Asia

January 31, 2014 3:00 AM UTC

Biogen Idec Inc. (NASDAQ:BIIB) granted UCB Group (Euronext:UCB) exclusive commercialization rights to Biogen Idec's multiple sclerosis and hemophilia therapies in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan. Biogen Idec retains commercialization rights in Japan. Additionally, Biogen Idec granted UCB rights to develop and commercialize Biogen Idec's products in China.

The deal includes Biogen Idec's MS drugs Tecfidera dimethyl fumarate and Tysabri natalizumab and two Biogen Idec products under FDA review for hemophilia: Eloctate rFVIIIFc for hemophilia A and Alprolix rFIXFc for hemophilia B. Biogen Idec said the partners are not disclosing financial details. ...